1 The Complexity of Tobacco Smoke-Induced Mutagenesis in Head and Neck Cancer

2

Laura Torrens¹, Sarah Moody², Ana Carolina de Carvalho¹, Mariya Kazachkova^{3,4,5}, Behnoush Abedi-3 Ardekani¹, Saamin Cheema², Sergey Senkin¹, Thomas Cattiaux¹, Ricardo Cortez Cardoso Penha¹, 4 Joshua R. Atkins⁶, Valérie Gaborieau¹, Priscilia Chopard¹, Christine Carreira⁷, Ammal Abbasi^{3,8,5}, Erik 5 6 N. Bergstrom^{3,5}, Raviteja Vangara^{3,5}, Jingwei Wang², Stephen Fitzgerald², Calli Latimer², Marcos Diaz-Gay^{3,5}, David Jones², Jon Teague², Felipe Ribeiro Pinto⁹, Luiz Paulo Kowalski¹⁰, Jerry Polesel¹¹, Fabiola 7 Giudici¹¹, José Carlos de Oliveira¹², Pagona Lagiou¹³, Areti Lagiou¹³, Marta Vilensky¹⁴, Dana Mates¹⁵, 8 Ioan N. Mates^{16,17}, Lidia M. Arantes¹⁸, Rui Reis¹⁸, Jose Roberto V. Podesta¹⁹, Sandra V. von Zeidler²⁰, 9 Ivana Holcatova²¹, Maria Paula Curado²², Cristina Canova²³, Elenora Fabianova²⁴, Paula A. Rodríguez-10 Urrego²⁵, Laura Humphreys², Ludmil B. Alexandrov^{3,26,5,27}, Paul Brennan¹, Michael R. Stratton², 11 Sandra Perdomo^{1*} 12

13

14 ¹Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France, ²Cancer, Ageing and Somatic Mutation, Wellcome Sanger Institute, Cambridge, UK, 15 ³Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, USA, 16 17 ⁴Biomedical Sciences Graduate Program, University of California San Diego, La Jolla, USA, ⁵Moores 18 Cancer Center, University of California San Diego, La Jolla, USA, ⁶Cancer Epidemiology Unit, The 19 Nuffield Department of Population Health, University of Oxford, Oxford, UK, ⁷Evidence Synthesis and 20 Classification Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France, ⁸Bioinformatics and Systems Biology Graduate Program, University of California San Diego, La Jolla, 21 USA, ⁹Brazilian National Cancer Institute, Rio de Janeiro, Brazil, ¹⁰University of São Paulo Medical 22 School, São Paulo, Brazil, ¹¹Unit of Cancer Epidemiology, Centro di Riferimento Oncologico di Aviano 23 24 (CRO) IRCCS, Aviano, Italy, ¹²Associação de Combate ao Câncer em Goiás Hospital Araújo Jorge, 25 Goiânia, Brazil, ¹³School of Medicine, National and Kapodistrian University of Athens, Athens, 26 Greece. ¹⁴Instituto de Oncología "Angel Roffo". Universidad de Buenos Aires, Buenos Aires, NOTE: This preprint reports new research that has not been certified by peer review and should not be used to duide clinical practice.

Argentina, ¹⁵National Institute of Public Health, Bucharest, Romania, ¹⁶Carol Davila University of 27 28 Medicine and Pharmacy, Bucharest, Romania, ¹⁷Saint Mary Clinic of General and Esophageal Surgery, 29 Bucharest, Romania, ¹⁸Barretos Cancer Hospital, Barretos, Brazil, ¹⁹Hospital Santa Rita de Cássia -Associação Feminina de Educação e Combate ao Câncer (AFECC), Vitória, Brazil, ²⁰Pathology 30 31 Department, Federal University of Espírito Santo, Vitória, Brazil, ²¹Charles University in Prague, 2nd 32 Faculty of Medicine, IPHPM, Prague, Czech Republic, ²²A.C.Camargo Cancer Center, São Paulo, Brazil, 33 ²³Unit of Biostatistics, Epidemiology and Public Health, Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padova, Italy, ²⁴Regional Authority of Public Health, 34 Slovak Republic, ²⁵Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia, 35 ²⁶Department of Bioengineering, University of California San Diego, La Jolla, USA, ²⁷Sanford Stem Cell 36 37 Institute, University of California San Diego, La Jolla, USA

38 * Corresponding author: Sandra Perdomo

39 ABSTRACT

40 Tobacco smoke, alone or combined with alcohol, is the predominant cause of head and neck cancer 41 (HNC). Here, we further explore how tobacco exposure contributes to cancer development by mutational signature analysis of 265 whole-genome sequenced HNC from eight countries. Six 42 tobacco-associated mutational signatures were detected, including some not previously reported. 43 44 Differences in HNC incidence between countries corresponded with differences in mutation burdens 45 of tobacco-associated signatures, consistent with the dominant role of tobacco in HNC causation. 46 Differences were found in the burden of tobacco-associated signatures between anatomical 47 subsites, suggesting that tissue-specific factors modulate mutagenesis. We identified an association between tobacco smoking and three additional alcohol-related signatures indicating synergism 48 between the two exposures. Tobacco smoking was associated with differences in the mutational 49 spectra and repertoire of driver mutations in cancer genes, and in patterns of copy number change. 50 51 Together, the results demonstrate the multiple pathways by which tobacco smoke can influence the 52 evolution of cancer cell clones.

53 INTRODUCTION

54 Head and neck cancer (HNC), including malignancies affecting the mouth, pharynx, and larynx, represents ~4% of the global cancer burden, with an annual incidence of about 750,000 new cases¹. 55 56 The incidence rate of HNC varies between different countries, largely reflecting the distribution of its main risk factors including tobacco smoking, alcohol consumption^{1,2}, and infection with high-risk 57 strains of human papillomavirus (HPV) for oropharynx cancer^{3–5}. Other proposed risk factors include 58 59 consumption of hot beverages, obesity, and poor oral health, although evidence for their role in HNC 60 is limited^{6–8}. In addition, a substantial proportion of head and neck cancers (about 42% for women 61 and 26% for men) cannot be attributed to known lifestyle habits or exposures⁹.

62

63 Epidemiological studies in Europe and America suggest that seven out of 10 HNC cancers are caused 64 by preventable behavioral risk factors, with tobacco use, either alone or in combination with alcohol, accounting for most cases⁹. Conversely, alcohol use on its own is responsible for only ~4% of the 65 66 disease burden, suggesting a limited impact on HNC burden. This raises the question of whether 67 alcohol acts as an independent carcinogen or simply enhances the known carcinogenic effect of tobacco. Furthermore, the susceptibility to these exposures varies depending on the anatomical 68 69 region, with smoking posing a higher risk for developing larynx cancer and the risk associated with alcohol being greater for other subsites¹⁰. 70

71

Considering the dominant role of tobacco in HNC development, risk differences across subsites, and potential interactions with other risk factors, HNC offers a particularly interesting opportunity to investigate the effects of tobacco exposure. In this context, the analysis of mutational signatures is an effective tool to track the complex mutagenic patterns linked to this and other exposures over a patient's lifetime^{11–13}. Certain mutational signatures have been related to well-established biological mechanisms and exposures. Signatures SBS4, found predominantly in lung cancer, and SBS92, in

58 bladder cancer, capture two distinct mutagenic processes linked to tobacco use^{12,14,15}. Conversely,

79 Signature SBS16 has been attributed to alcohol consumption in esophageal and liver cancer^{13,16}.

80

81 Previous studies exploring the genomic landscape of HNC have relied predominantly on exome 82 sequencing data, which has limited power to detect mutational signatures, lacked a diverse 83 geographical and ethnic representation of cases, and/or were limited to specific anatomical subsites^{17–20}. Therefore, the carcinogenic mechanisms underpinning this cancer type in different 84 85 geographical regions and anatomical subsites remain unclear. To bridge this gap, we performed whole-genome sequencing of 265 HNC cases from individuals exposed to known and suspected risk 86 factors across eight countries with varying incidence rates. By leveraging mutational signature 87 88 analysis combined with extensive epidemiological data, we shed light on the complexity of tobacco-89 induced mutagenesis and its interplay with alcohol consumption and other HNC risk factors.

90 **RESULTS**

91 Case-series overview and multi-country study design

92 A total of 265 HNC cases were included in the study, comprising retrospective collections from eight countries in Europe and South America^{6,21} (Figure 1; Supplementary Table 1). These encompass a 93 broad geographic representation of HNC, including cases from high-incidence regions, with sex-94 95 combined age-standardized rates (ASR) ranging from 9.4 per 100,000 to 18.2 per 100,000 in 96 Romania, Slovakia, Czech Republic, and Brazil, as well as moderate-incidence regions, with ASR from 97 3.8 to 7.8 per 100,000, in Colombia, Argentina, Greece, and Italy¹. The dataset contains cases from 98 all HNC anatomical subsites, with 127 oral cavity, 46 oropharynx, 17 hypopharynx, and 75 larynx 99 cancers. Epidemiological questionnaire data were available on exposure to known and suspected 100 HNC risk factors, including cases from drinkers, smokers, with both exposures, and non-exposed. 101 DNAs from paired tumor and blood samples were extracted and whole-genome sequenced to 102 average coverage of 55-fold and 27-fold, respectively.

103

104 Mutation burden

105 Among the 265 HNC cases, we observed a median of 12,887 single-base substitutions (SBS, range: 106 720 to 244,026), 63 doublet-base substitutions (DBS, range: two to 7,113), and 757 small insertions 107 and deletions (ID, range: 124 to 9,898; Supplementary Table 2). Tumor samples from tobacco users 108 exhibited higher SBS, DBS, and ID burdens compared to non-smokers (Extended Data Figure 1b; Supplementary Table 3), as previously reported for larynx cancer¹⁴. Differences were also found 109 110 between anatomical subsites, with larynx samples presenting higher mutation burdens, even after 111 correcting for tobacco status (Extended Data Figure 1a; Supplementary Table 3). No significant 112 differences were found between geographical regions (Extended Data Figure 1c).

114 Mutational signatures of exogenous and endogenous exposures

To investigate the mutational processes and carcinogenic exposures that have been operative in HNC development, we extracted SBS, DBS, and ID signatures and estimated the contribution of each signature to every sample. We obtained 15 *de novo* SBS signatures, which were decomposed into 18 reference signatures from the Catalogue of Somatic Mutations in Cancer (COSMICv3.2) database, and two signatures that could not be decomposed into any combination of existing signatures, SBS_I and SBS_L (Figure 2a-b; Extended Data Figure 2; Supplementary Tables 4,7-9, Supplementary Note).

122

Among the identified signatures, several have been previously associated with exogenous mutational processes¹². The tobacco-related signatures SBS4 and SBS92 were found in 34% and 7.6% of HNC samples and respectively accounted for 6.3% and 3.5% of the mutational burden on average. SBS16, attributed to alcohol consumption^{13,16}, was present in 19% of the samples with a modest impact on the HNC mutation burden of 1.4% on average. Signatures of ultraviolet (UV) light exposure SBS7a and SBS7b co-occurred in 4.2% of cases.

129

We also identified signatures associated with endogenous exposures and aberrant cellular processes. Notably, SBS2 and SBS13, which result from cytosine deamination by Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC)¹⁴, were present in the majority of HNC cases (93% and 92%, respectively; **Figure 2a**) and were highly correlated (**Supplementary Figure 1**). Combined, these signatures accounted for an average of 20.4% of the total SBS mutation burden. Other prevalent signatures included SBS18, which is caused by reactive oxygen species (77% of samples), and clock-like signatures SBS1 (78%) and SBS5 (55%) (**Figure 2a**).

137

Extraction of DBS signatures identified four *de novo* signatures, which decomposed into four COSMIC
 reference signatures (DBS1, DBS2, DBS4, and DBS6) and one non-decomposed signature (DBS_D;

140 Figure 2a-b; Extended Data Figure 3a; Supplementary Tables 5,7-9). We also extracted seven de 141 novo ID signatures, all of which were decomposed into 12 COSMIC signatures (Figure 2a-b; Extended 142 Data Figure 3b; Supplementary Tables 6-9). DBS and ID signatures of exogenous exposures were positively correlated with their SBS counterparts (Supplementary Figure 1). For instance, the known 143 144 tobacco-related signatures DBS2 (59% of samples) and ID3 (41%), along with DBS6 which has been previously registered as of unknown etiology, correlated with both SBS4 and SBS92. These 145 146 associations are consistent with these SBS, DBS, and ID signatures being generated by the same 147 underlying mutational process. Similarly, ID11 (38%), which was associated with alcohol consumption in esophageal cancer¹³, exhibited a positive correlation with the alcohol signature 148 149 SBS16, while UV-related DBS1 (16.6%) and ID13 (1.5%) signatures showed the same link with SBS7a-

150 c.

151

152 To establish which mutagenic exposures were active earlier or later during the development of HNC, 153 we estimated the molecular timing of each SBS signature (Methods). Signatures of tobacco and 154 alcohol consumption, as well as the SBS L signature, were enriched in early clonal mutations 155 (Extended data Figure 4), consistent with carcinogenic exposures occurring in normal cells²². Similarly, SBS_I was significantly enriched in early clonal mutations in oral cavity cases, while no 156 157 significant differences were seen in other subsites. Signatures of APOBEC signaling and SBS39 were 158 enriched in late clonal mutations, suggesting that the corresponding mutational processes increased in activity during the evolution of cancer clones²². 159

160

161 HNC tumors present complex tobacco-related mutation patterns

Several signatures were independently associated with tobacco consumption, including the previously-recognized tobacco-related signatures SBS4, SBS92, DBS2, and ID3, as well as signature DBS6, reported as of unknown etiology, and the newly-discovered SBS_I (**Figure 3a-b**; **Supplementary Table 10; Supplementary Note**). The tobacco-associated SBS signatures were 166 composed of three different substitution patterns (predominantly C>A for SBS4, T>C for SBS92, and 167 T>A for SBS_I; Figure 2c) and exhibited transcriptional strand bias (Supplementary Figure 4)^{15,23}. This 168 strand bias towards the transcribed strand often occurs as a result of transcription-coupled DNA 169 repair and is found in mutations due to bulky adducts, caused by exogenous exposures such as 170 tobacco smoke carcinogens²³. Assuming this mechanism is responsible for the strand bias in SBS_I, 171 this is indicative of adduct formation on adenine bases.

172

173 The distribution of tobacco-associated signatures varied across different anatomical subsites (Figure 174 3a, Extended Data Figure 5a; Supplementary Table 10). Previously established tobacco signatures 175 exhibited higher signature burdens and frequencies in larynx cases compared to other subsites. For 176 instance, SBS4 was present in 17% of OC, 17% of oropharynx, 53% of hypopharynx, and 67% of 177 larynx cases. Similar distributions were observed for SBS92, DBS2, and ID3. Conversely, the 178 previously unknown SBS I signature was present in smokers across all subsites, with particular 179 enrichment in the oral cavity. The associations between signatures and subsites remained significant 180 after correction for tobacco consumption and other confounding variables (Supplementary Table 10). 181

182

183 Effects of tobacco exposure on the driver mutation spectra

184 We explored the driver mutation profile in tobacco-related HNC. This revealed 96 cancer genes with 185 driver mutations in our dataset, including TP53, NOTCH1, CDKN2A, KMT2D, and CASP8, which are commonly implicated in HNC²⁴ (Extended Data Figure 6a-b; Supplementary Tables 11-12). TP53 186 187 mutations were significantly enriched among smokers compared to non-smokers (83% [164/197] vs 61% [42/68], p=0.001), while CASP8 mutations were more frequent among non-smokers (6.09% 188 189 [12/197] vs 20.6% [14/68], p=0.003). A total of 642 driver mutations were identified (Methods), and 190 these showed an enrichment of C>A substitutions in smokers compared to non-smokers (24.9% 191 [114/457] vs 17.3% [32/185], Fisher's exact test p=0.0379; Extended Data Figure 6c), consistent with

the SBS4 mutation profile¹². The frequency of C>A driver mutations in tobacco-exposed cases was higher in the larynx subsite compared to oral cavity (31.5% [53/168] vs 19.9% [38/191], Fisher's exact test p=0.0148; **Figure 3c-d**). This reflects the lower contribution of SBS4 to mutations in tobacco-exposed oral cavity HNC compared to larynx cases, which has been carried through into the generation of driver mutations. T>A driver mutations were also observed among smokers, albeit in low frequencies (6.6% [11/168] in larynx and 8.4% [16/191] in oral cavity, hinting at a lower presence of SBS_I in driver mutations.

199

200 Tobacco-related mutational signatures correlate with demographic HNC incidence

We analyzed the link between tobacco mutagenesis and variations in HNC incidence across different countries, sexes, and anatomical subtypes. Our findings support previous epidemiological evidence, which has shown a connection between HNC incidence and smoking habits² (Figure 4a-b). Moreover, HNC incidence correlated with tobacco-related signatures (Figure 4c; Supplementary Figure 2), showing a higher ASR of HNC incidence in demographic groups presenting higher signature burdens. This further confirms that the geographical and demographic differences in tobacco exposure play a dominant role in driving HNC incidence.

208

209 Alcohol-related mutational signatures in drinkers and smokers

210 Next, we assessed the signature profile in HNC cases with a history of alcohol intake. Our analysis 211 revealed significant associations between alcohol consumption and three specific signatures: SBS16, 212 ID11, and DBS4 (Figure 5; Supplementary Table 10; Supplementary Note). SBS16 was present 213 exclusively in HNC cases from drinkers and showed enrichment in samples exposed to both tobacco 214 and alcohol compared to alcohol alone (29.0% [47/162] and 12.5% [4/32], respectively). Similarly, 215 DBS4 and ID11 also presented higher burdens and signature frequencies in cases exposed to both risk factors (Figure 5; Supplementary Table 10). Although the etiology of DBS4 is unclear, it has been 216 217 found prevalent in esophageal cancer cases from countries with high alcohol intake rates¹³. The

results are, therefore, consistent with SBS16, DBS4 and ID16 all being generated by the same underlying alcohol-related mutational process and that the mutagenicity of this process is increased with co-exposure to tobacco smoke.

221

For driver mutations, samples from individuals exposed to both tobacco and alcohol were 222 characterized by a particularly high TP53 frequency of mutations (87.0% [141/162], 71.4% [25/35], 223 224 68.8% [22/32], and 55.6% [20/36] in the tobacco plus alcohol, alcohol alone, tobacco alone, and 225 unexposed groups, respectively, Fisher's exact test p=0.0001; Extended Data Figure 6; Supplementary Table 11). The driver mutation burden in the SBS16 context was too low to assess 226 227 differences in the driver spectra between groups. However, TP53 mutations in the SBS16 contexts 228 were exclusively found in samples from individuals exposed to both tobacco and alcohol (n=5 TP53 229 variants).

230

231 HPV-positive HNC is characterized by APOBEC signatures

HPV infection in oropharynx cases did not elicit a specific mutational signature profile (Supplementary Table 10). However, the substitution profile in HPV-positive oropharyngeal HNC was characterized by a higher relative proportion of APOBEC signatures, with 57.6% of the signature burden being attributed to SBS2 and SBS13 on average, compared to 30.0% in HPV-negative oropharynx (Extended Data Figure 7a) consistent with previous reports¹⁸. Notably, the presence of APOBEC signatures was nearly ubiquitous across HNC cases (Figure 2a), suggesting a broader role for APOBEC activation beyond its anti-viral function¹¹.

239

We also observed differences between HPV-positive and HPV-negative oropharynx cases exposed to tobacco. Among smokers, only 1/6 (17%) HPV-positive oropharynx cases presented tobacco-related SBS signatures, compared to 7/26 (27%) in HPV-negative cases (Fisher's exact test p=0.0214). Despite the well-known influence of tobacco smoking on the driver profiles of HNC^{20,24}, the driver

alterations in HPV-positive smokers differed from that of HPV-negative smokers, and instead
 resembled the profile in HPV-positive cases from non-smokers. This included *PIK3CA* mutations,
 PTEN mutations and deletions, as well as absence of *TP53* mutations and of *FADD* gains (Extended
 Data Figure 7b-c). This, together with the reduced presence of tobacco-related signatures, suggests
 that oncogenesis in HPV-positive smokers may primarily be driven by viral infection rather than
 tobacco exposure.

250

251 Mutational signature profile in samples exposed to putative HNC risk factors

252 We next investigated the presence of additional environmental exposures beyond the most widely-253 known HNC risk factors. Notably, UV-related signatures SBS7a-c, DBS1, and ID13 were detected 254 predominantly in oral cavity cases (Figure 6a; Supplementary Table 10; Supplementary Note). SBS7 255 signatures have been previously described in HNC, but the anatomical and epidemiological features 256 of positive cases have not been previously investigated¹². Samples with a relative SBS7a-c burden of 257 >10% were categorized as positive for UV exposure, a criterion met by 13 oral cavity cases from the 258 lip, tongue, and floor of the mouth (Figure 6b). All positive cases were either tobacco or alcohol 259 users, with 11/13 presenting both risk factors (Figure 6b). Thus, our data suggests a potential role of 260 UV light exposure in HNC carcinogenesis²³, which could be enhanced by tobacco and/or alcohol.

261

Our analysis did not show any specific mutational patterns associated with other putative HNC risk factors, including hot drink consumption, poor oral health score, and high body mass index^{6,7} (**Supplementary Table 10**). This suggests that these agents are likely not causing direct mutagenesis. Finally, the previously unknown DBS_D signature and ID4, with unknown etiology, were enriched among non-smokers (**Extended Data Figure 5b**), suggesting a potential link to unidentified mutational processes in this population.

268

269 HNC risk factors elicit distinct copy number profiles

HNC is characterized by complex patterns of copy number (CN) aberrations throughout the genome^{19,20}. Unsupervised hierarchical clustering analysis on the CN counts in HNC samples (*n*=242) revealed two main clusters, one displaying diploid genomes (cluster D), and another presenting polyploidy and high burden of CN gains and losses (cluster P; **Extended Data Figure 8**; **Supplementary Figure 3**). These clusters further subdivided into four groups (D1, D2, P1, and P2). Notably, subgroup D2 was characterized by a CN-neutral profile, exhibiting significantly lower burdens of CN events compared to the other groups.

277

The CN clusters were associated with distinct epidemiological profiles (Figure 7c-d; Supplementary 278 279 Table 13). Specifically, tobacco-related HNC were enriched within both the diploid and polyploid CN-280 high clusters (i.e., D1, P1, and P2), while the CN-silent cluster D2 was mostly constituted by samples 281 from non-smokers, including cases with unknown risk factors and alcohol drinkers in the absence of 282 tobacco. Consistent with this pattern, the D2 cluster was enriched in samples from female patients, 283 oral cavity cases, and older age, aligning with the characteristic features of HNC with undefined risk factor²⁴. Finally, HPV-positive oropharynx cases were enriched in the diploid clusters, predominantly 284 285 in cluster D1.

286

287 To unveil distinct CN particularities within each CN cluster and etiology, we conducted CN signature 288 analysis²⁵ (Figure 7a-b; Extended Data Figure 9; Supplementary Note). Cluster D1 exhibited 289 enrichment in signatures of chromosomal instability within a diploid genome background (signatures 290 CN1, CN9 and CN13; Extended Data Figure 10a). In contrast, cluster D2 presented a signature profile 291 related to a diploid copy-neutral background (CN1). Clusters P1 and P2 displayed associations with signatures of whole-genome duplication (CN2, CN20) along with genomic aberrations (CN5, CN_G; 292 293 Extended Data Figure 10b-c). Cluster P1 was consistent with double whole-genome duplications 294 (CN18), while P2 showed signatures of chromosomal instability in conjunction with genome doubling

(CN12). Collectively, our analysis suggests that HNC risk factors align with different CN profiles and
provides an enhanced characterization of the CN aberrations in each HNC etiology (Figure 7d).
Specifically, tobacco use, alone or with alcohol, may trigger chromosomal instability and aneuploidy,
while HPV infection may confer a CN unstable diploid profile. Lastly, samples with unknown risk
factors exhibit a CN-neutral profile.

300

We explored whether this difference in the CN profile could be due to the driver profile that is associated with each risk factor (**Figure 7d**; **Extended Data Figure 10d**). *TP53* mutations and *MYC* gains, two known promoters of genomic instability^{25–27}, as well as gains in the anti-apoptotic *FADD* gene, were enriched in cluster P. *CASP8* and *HRAS* mutations were enriched in the D2 CN-neutral cluster, in agreement with previous studies in HNC^{20,24,25}. Finally, *PTEN* and *RB1* mutations were enriched in the D1 cluster. Overall, these results show that tobacco use in HNC is associated with a distinct CN-rich profile and driver alterations related to genome instability.

308 DISCUSSION

The role of tobacco as one of the most avoidable cancer risk factors has been known for over 50 years. Yet, the detailed mechanisms by which tobacco smoke leads to DNA damage and carcinogenesis in different tissues are still not fully understood^{14,28,29}. In this study encompassing HNC cases from eight countries in Europe and South America, we shed light on the effects of tobacco as the main mutagenic exposure in HNC and explored the complex mutational patterns and genomic alterations linked to tobacco exposure in different HNC subsites, as well as its interplay with alcohol consumption and other risk factors.

316

Tobacco smoke contains a mixture of thousands of chemicals, including over 60 carcinogens, among 317 318 which benzo[a]pyrenes (BaP) and nitrosamines are the most widely studied. These carcinogens 319 undergo metabolic activation, generating reactive intermediates that interact with DNA in exposed 320 tissues, resulting in complex mutagenic processes that can lead to cancer development²⁹. In HNC, 321 tobacco exposure resulted in six different signatures, unveiling at least three mutational processes 322 due to tobacco in HNC. Signature SBS4, characterized by C>A transversions, has been largely attributed to BaP adducts^{14,30,31}. Exposure to this compound is also consistent with the CC>AA 323 substitutions and C deletions present in DBS2 and ID3 tobacco signatures, respectively³¹. Conversely, 324 signature SBS92, composed predominantly of T>C transitions, has not been related to specific 325 carcinogens in tobacco smoke¹⁵. Finally, the T>A-rich substitution profile captured by the previously-326 327 unidentified signature SBS_I is compatible with adduct formation on adenines, which have been observed in response to multiple tobacco compounds^{31–33}. Among those, exposure to nicotine-328 329 derived nitrosamine ketone (NNK), one of the main tobacco carcinogens in oral tissues³⁴, also yielded a T>A-rich signature in vitro^{35,36}. Notably, a signature exhibiting high T>A frequencies and 330 transcriptional strand bias has been described in normal lung epithelia from patients with a history 331 332 of smoking³⁷.

334 Our epidemiological analysis revealed that the mutational effects of tobacco vary among anatomical 335 subsites. The canonical tobacco signatures SBS4 and SBS92 were found predominantly in larynx 336 cases, along with the tobacco-related DBS and ID signatures. Conversely, SBS_I was extracted in HNC 337 cases from all subsites, with a notable enrichment in oral cavity cases. Altogether, our observations 338 hint at varying susceptibility, exposure level, or clearance of tobacco carcinogens across tissues, 339 leading to different genotoxic effects. A possible explanation for these differences is the tissue-340 specific pattern of cytochrome P450 function. CYP1A1, the main BaP metabolizer, is primarily 341 expressed in lung and larynx, whereas enzymes responsible for nitrosamine metabolism, such as CYP2E1, are predominant in the upper aerodigestive tract including the oral cavity^{34,38–40}. These 342 343 differences in the response to tobacco across tissues may partially explain the greater susceptibility to smoking found for larynx cancers compared to other anatomical subsites¹⁰. While tobacco use 344 345 was associated with elevated mutation burdens and BaP-related driver mutations in larynx cancers, 346 this was not observed in oral cavity cases, aligning with a reduced carcinogenic effect. Thus, 347 additional carcinogenic processes may be necessary to aid in the development of oral cavity and 348 oropharynx cancers, including alcohol and HPV infection¹⁰.

349

In this regard, we also identified mutagenic processes linked to alcohol exposure^{13,16}, including 350 351 signatures SBS16, ID11, and an unreported association with signature DBS4. In HNC, alcohol-related 352 signatures were predominantly observed in patients reporting both alcohol and tobacco consumption, reflecting the synergistic effect between these two factors on disease risk^{9,41}. 353 354 Furthermore, a previous study suggested an enrichment of SBS16 in oropharynx cases from tobacco 355 users¹⁸. Altogether, our findings indicate that tobacco could enhance the carcinogenic effects of 356 alcohol through shared mutagenic processes. Experimental evidence suggests that salivary concentrations of acetaldehyde, the genotoxic byproduct of alcohol metabolism, are greatly 357 increased by tobacco smoking⁴², which could result in enhanced alcohol-related mutagenesis in 358 359 cases with combined exposure.

360

Our data show that tobacco use, alone or in conjunction with alcohol, is also associated with a 361 distinct CN-rich profile, characterized by CN signatures of chromosomal instability, and resembling a 362 previously described subset of CN-rich HNC¹⁹. These genomic profiles are likely due to driver 363 alterations leading to genome instability such as TP53 mutations, which are prevalent among 364 smokers and drinkers²⁴. Although high CN burdens have been reported in lung adenocarcinoma 365 cases from smokers¹⁴, the link between this exposure and specific CN or driver profiles in HNC was 366 367 previously unclear⁴³. Cases with unknown etiology, on the other hand, exhibit few CN alterations, prevalence of CASP8 and HRAS mutations, and wild-type TP53. A similar CN-neutral group of 368 samples has been observed in HNC, with an unreported link with HNC etiology^{19,44}. 369

370

371 Regarding the mutagenic potential of other investigated risk factors, HPV infection did not elicit a 372 specific mutational signature profile, but it was associated with distinct driver mutations and a CNunstable diploid genome. Poor oral hygiene, high body mass index, and consumption of hot drinks 373 374 did not display a direct effect on the mutation profile of HNC cases and likely contribute to the development of HNC of unknown etiology through mechanisms distinct from direct mutagenesis. 375 This pattern has been proposed for several carcinogens in prior studies^{13,45}. Nevertheless, there may 376 377 exist additional unidentified mutagens leading to HNC, as hinted by the presence of the previously 378 unidentified signature SBS_L as well as the enrichment of DBS_D and ID4 among non-smokers.

379

Furthermore, we provide evidence suggesting that sunlight exposure may contribute to HNC development. Specifically, we identified signatures consistent with pyrimidine dimer formation (SBS7a-c and DBS1) in oral HNC cases, indicative of DNA damage by UV light^{12,23}. UV light has only been described as a risk factor for malignancies in the external lip⁴⁶, but experimental evidence suggests that oral cavity epithelia are susceptible to this exposure, and its carcinogenic processes could be enhanced by tobacco smoking^{47–51}. While we cannot exclude the possibility of other

386	mutational processes eliciting CC>TT substitutions, such as those driven by reactive oxygen species ⁵² ,
387	the presence of ID13 signatures, identified in melanoma ¹² , provides additional evidence supporting
388	the role of sunlight exposure in oral HNC.
389	

- 390 In summary, through our comprehensive analysis of the mutational, genomic, and epidemiological
- 391 profile of HNC cases from diverse geographical regions, we have uncovered genomic mechanisms by
- 392 which tobacco smoke and other risk factors contribute to HNC development. These findings enhance
- 393 our understanding of the complexity and tissue-specificity of tobacco mutagenesis, offering
- additional evidence that may inform prevention strategies aimed at reducing the risk of this disease.

395 **REFERENCES**

396	1.	Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality
397		worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71 , 209–249 (2021).
398	2.	Simard, E. P., Torre, L. A. & Jemal, A. International trends in head and neck cancer incidence
399		rates: differences by country, sex and anatomic site. Oral Oncol 50, 387–403 (2014).
400	3.	Alcohol Consumption and Ethyl Carbamate. Alcohol Consumption and Ethyl Carbamate
401		(2010).
402	4.	IARC Working Group on the Evaluation of Carcinogenic Risks to Humans., World Health
403		Organization. & International Agency for Research on Cancer. Tobacco Smoke and Involuntary
404		Smoking. (IARC Press, 2004).
405	5.	International Agency for Research on Cancer, (IARC) & World Health Organization, (WHO).
406		Human Papillomaviruses. Human papillomaviruses vol. 90 (2007).
407	6.	Hashim, D. et al. The role of oral hygiene in head and neck cancer: results from International
408		Head and Neck Cancer Epidemiology (INHANCE) consortium. Annals of Oncology 27, 1619
409		(2016).
410	7.	Gaudet, M. M. et al. Body mass index and risk of head and neck cancer in a pooled analysis of
411		case-control studies in the International Head and Neck Cancer Epidemiology (INHANCE)
412		Consortium. Int J Epidemiol 39 , 1091–1102 (2010).
413	8.	Loomis, D. et al. Carcinogenicity of drinking coffee, mate, and very hot beverages. Lancet
414		Oncol 17 , 877–878 (2016).
415	9.	Hashibe, M. et al. Interaction between tobacco and alcohol use and the risk of head and neck
416		cancer: Pooled analysis in the international head and neck cancer Epidemiology consortium.
417		Cancer Epidemiology Biomarkers and Prevention 18 , 541–550 (2009).
418	10.	Lubin, J. H. et al. Total Exposure and Exposure Rate Effects for Alcohol and Smoking and Risk
419		of Head and Neck Cancer: A Pooled Analysis of Case-Control Studies. Am J Epidemiol 170,
420		937–947 (2009).

421	11.	Perdomo, S. et al. The Mutographs biorepository: A unique genomic resource to study cancer
422		around the world. Cell Genomics 100500 (2024) doi:10.1016/J.XGEN.2024.100500.
423	12.	Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578,
424		94–101 (2020).
425	13.	Moody, S. et al. Mutational signatures in esophageal squamous cell carcinoma from eight
426		countries with varying incidence. Nat Genet 53, 1553–1563 (2021).
427	14.	Alexandrov, L. B. et al. Mutational signatures associated with tobacco smoking in human
428		cancer. Science 354 , 618–622 (2016).
429	15.	Islam, S. M. A. et al. Uncovering novel mutational signatures by de novo extraction with
430		SigProfilerExtractor. Cell Genomics 2, 100179 (2022).
431	16.	Letouzé, E. et al. Mutational signatures reveal the dynamic interplay of risk factors and
432		cellular processes during liver tumorigenesis. Nat Commun 8, 1315 (2017).
433	17.	Plath, M. et al. Unraveling most abundant mutational signatures in head and neck cancer. Int
434		J Cancer 148 , 115–127 (2021).
435	18.	Gillison, M. L. et al. Human papillomavirus and the landscape of secondary genetic alterations
436		in oral cancers. <i>Genome Res</i> 29 , 1–17 (2019).
437	19.	Yang, J., Chen, Y., Luo, H. & Cai, H. The Landscape of Somatic Copy Number Alterations in
438		Head and Neck Squamous Cell Carcinoma. Front Oncol 10, 479033 (2020).
439	20.	Sayáns, M. P. et al. Comprehensive Genomic Review of TCGA Head and Neck Squamous Cell
440		Carcinomas (HNSCC). Journal of Clinical Medicine 2019, Vol. 8, Page 1896 8, 1896 (2019).
441	21.	Slot, D. E., Van Der Weijden, F. & Ciancio, S. G. Oral health, dental care and mouthwash
442		associated with upper aerodigestive tract cancer risk in Europe: the ARCAGE study. Oral
443		<i>Oncol</i> 50 , e57 (2014).
444	22.	Gerstung, M. et al. The evolutionary history of 2,658 cancers. Nature 2020 578:7793 578,
445		122–128 (2020).

- 446 23. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–
- 447 421 (2013).
- 24. Leemans, C. R., Snijders, P. J. F. & Brakenhoff, R. H. The molecular landscape of head and neck
- 449 cancer. *Nat Rev Cancer* **18**, 269–282 (2018).
- 450 25. Steele, C. D. et al. Signatures of copy number alterations in human cancer. Nature 2022
- 451 *606:7916* **606**, 984–991 (2022).
- 452 26. Meyer, N. & Penn, L. Z. Reflecting on 25 years with MYC. *Nature Reviews Cancer 2008 8:12* 8,
 453 976–990 (2008).
- 454 27. Steele, C. D., Pillay, N. & Alexandrov, L. B. An overview of mutational and copy number
- 455 signatures in human cancer. J Pathol **257**, 454 (2022).
- 456 28. Cogliano, V. J. et al. Preventable exposures associated with human cancers. J Natl Cancer Inst
- 457 **103**, 1827–1839 (2011).
- 458 29. Hecht, S. S. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. *Nature*459 *Reviews Cancer 2003 3:10* 3, 733–744 (2003).
- 30. Nik-Zainal, S. *et al.* The genome as a record of environmental exposure. *Mutagenesis* **30**, 763
 461 (2015).
- 462 31. Kucab, J. E. *et al.* A Compendium of Mutational Signatures of Environmental Agents. *Cell* 177,
 463 821-836.e16 (2019).
- Westcott, P. M. K. *et al.* The mutational landscapes of genetic and chemical models of Krasdriven lung cancer. *Nature* 517, 489 (2015).
- 466 33. Pfeifer, G. P. *et al.* Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-
- 467 associated cancers. *Oncogene 2002 21:48* **21**, 7435–7451 (2002).
- 468 34. Hecht, S. S. & Hatsukami, D. K. Smokeless Tobacco and Cigarette Smoking: Chemical
- 469 Mechanisms and Cancer Prevention. *Nat Rev Cancer* **22**, 143 (2022).
- 470 35. Peterson, L. A. Context matters: Contribution of specific DNA adducts to the genotoxic
- 471 properties of the tobacco-specific nitrosamine NNK. *Chem Res Toxicol* **30**, 420–433 (2017).

472	36.	Mingard, C. et al. Dissection of Cancer Mutational Signatures with Individual Components of
473		Cigarette Smoking. Chem Res Toxicol 36 , 714–723 (2023).
474	37.	Yoshida, K. et al. Tobacco smoking and somatic mutations in human bronchial epithelium.
475		Nature 578 , 266–272 (2020).
476	38.	Degawa, M. et al. Metabolic activation and carcinogen-DNA adduct detection in human
477		larynx. <i>Cancer Res</i> 54, 4915–9 (1994).
478	39.	Jones, N. J., McGregor, A. D. & Waters, R. Detection of DNA adducts in human oral tissue:
479		correlation of adduct levels with tobacco smoking and differential enhancement of adducts
480		using the butanol extraction and nuclease P1 versions of 32P postlabeling. Cancer Res 53,
481		1522–8 (1993).
482	40.	Yamazaki, H., Inui, Y., Yun, C. H., Guengerich, F. P. & Shimada, T. Cytochrome P450 2E1 and
483		2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and
484		tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13, 1789–1794
485		(1992).
486	41.	Hoes, L., Dok, R., Verstrepen, K. J. & Nuyts, S. Ethanol-Induced Cell Damage Can Result in the
487		Development of Oral Tumors. Cancers 2021, Vol. 13, Page 3846 13, 3846 (2021).
488	42.	Gapstur, S. M. et al. The IARC Perspective on Alcohol Reduction or Cessation and Cancer Risk.
489		(2023).
490	43.	Pickering, C. R. et al. Squamous cell carcinoma of the oral tongue in young non-smokers is
491		genomically similar to tumors in older smokers. Clin Cancer Res 20, 3842–3848 (2014).
492	44.	Lawrence, M. S. et al. Comprehensive genomic characterization of head and neck squamous
493		cell carcinomas. <i>Nature 2015 517:7536</i> 517 , 576–582 (2015).
494	45.	Riva, L. et al. The mutational signature profile of known and suspected human carcinogens in
495		mice. <i>Nat Genet</i> 52 , 1189–1197 (2020).

- 496 46. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans., World Health
- 497 Organization. & International Agency for Research on Cancer. *Solar and Ultraviolet Radiation*.

498 (IARC, 1992).

- 499 47. Agrawal, A. *et al.* UV radiation increases carcinogenic risks for oral tissues compared to skin.
- 500 *Photochem Photobiol* **89**, 1193–1198 (2013).
- 501 48. von Koschembahr, A. et al. Solar simulated light exposure alters metabolization and
- 502 genotoxicity induced by benzo[a]pyrene in human skin. *Scientific Reports 2018 8:1* 8, 1–12
- 503 (2018).
- 49. King, G. N. et al. Increased prevalence of dysplastic and malignant lip lesions in renal-
- 505 transplant recipients. *N Engl J Med* **332**, 1052–1057 (1995).
- 506 50. Sugano, N., Minegishi, T., Kawamoto, K. & Ito, K. Nicotine inhibits UV-induced activation of
- 507 the apoptotic pathway. *Toxicol Lett* **125**, 61–65 (2001).
- 508 51. Onoda, N. *et al.* Nicotine affects the signaling of the death pathway, reducing the response of
 509 head and neck cancer cell lines to DNA damaging agents. *Head Neck* 23, 860–870 (2001).
- 510 52. Reid, T. M. & Loeb, L. A. Tandem double CC-->TT mutations are produced by reactive oxygen
- 511 species. *Proc Natl Acad Sci U S A* **90**, 3904 (1993).

512

514 FIGURE AND TABLE LEGENDS

Figure 1. Head and neck cancer incidence and epidemiological characteristics. a, Incidence of head 515 516 and neck cancer (HNC), sex-combined, age-standardized rates (ASR) per 100,000, data from 517 GLOBOCAN 2022. Dots indicate countries included in this study and number of participating patients. b, Anatomical subsites of HNC, with number of tumor samples indicated in brackets. 518 519 Created with biorender.com c, Known and suspected risk factors included in the study, based on 520 epidemiological questionnaire data and human papillomavirus (HPV) detection. Frequencies of risk 521 factors in the complete dataset (left) and by anatomical subsite (right) are indicated. OC, oral cavity; 522 OPC, oropharynx; HPX, hypopharynx; LYX, larynx.

523

524 Figure 2. Mutational signature landscape of head and neck cancer. a, Single base substitution (SBS), 525 doublet base substitution (DBS), and insertion deletion (ID) signatures extracted in 265 HNC tumors. 526 The size of each dot represents the proportion of samples presenting each mutational signature in 527 the whole HNC dataset and across anatomical subsites. The color represents the mean relative attribution of each signature. Gray dots indicate signatures without significantly different relative 528 529 burdens by subsite. The top panel shows the mutations per megabase attributed to each signature 530 in samples with counts higher than zero. Significance was assessed using a two-sided Kruskal-Wallis 531 test and Bonferroni correction. b, Mutational spectrum of undecomposed signatures extracted from 532 HNC. c, Known signatures of tobacco exposure identified in the HNC dataset. HNC, head and neck cancer; OC, oral cavity; OPC, oropharynx; ROS, reactive oxygen species; HR, homologous 533 recombination; DSB, double-strand break. 534

535

Figure 3. Tobacco-related signatures. a, Mutational burdens of tobacco-related signatures in HNC cases sorted by subsite and tobacco status. Tumor mutational burdens (TMB) per sample is also displayed. For clarity, y axis has been cut at 100,000 for TMB and at 15,000 for SBS_I. b, Mutational burdens for SBS, DBS, and ID signatures showing significant positive associations with tobacco

540 consumption (n = 265 biologically independent samples). The Kruskal–Wallis test (two sided) was 541 used to test for global differences. Box-and-whisker plots are in the style of Tukey. The line within the box is plotted at the median, while upper and lower ends indicate 25th and 75th percentiles. 542 Whiskers show 1.5 × interguartile range (IQR), and values outside it are shown as individual data 543 544 points. Y axes were cut at 1.25 × upper whisker for clarity. Bar plots indicate the frequencies of 545 dichotomized signatures. c, Percentage of driver mutations occurring in C>A contexts in larynx and 546 oral cavity HNC from smokers. d, SBS96-mutation spectrum of driver mutations in larynx and oral 547 cavity HNC from smokers, showing enrichment in the frequency of C>A driver mutations in larynx 548 cases. HPX, hypopharynx.

549

Figure 4. Association of tobacco use with incidence of head and neck cancer. a, Correlation 550 551 between age-standardized rate (ASR) of HNC incidence and tobacco smoking per country and sex. 552 Estimate of ASR of tobacco smoking prevalence was obtained from WHO Global Health Observatory 553 (2019). b, Association between cigarette quantity smoked per day in the HNC dataset and ASR incidence per country, sex, and subsite. c, Association of tobacco-related signatures with ASR 554 555 incidence. Number of mutations attributed to tobacco-related SBS (SBS4, SBS92, SBS I), DBS (DBS2, 556 DBS6), and ID (ID3) mutational signatures against ASR of HNC per country, sex, and subsite. For b and c, The p-values shown are for ASR variable in regressions across all cases, adjusted for age. The 557 558 frequency of the signatures and number of cases per country, sex, and subsite are indicated. OC, oral 559 cavity; OPC, oropharynx.

560

Figure 5. Alcohol-related signatures. a, Mutational burdens of tobacco-related signatures in HNC cases sorted by subsite, alcohol, and tobacco status. Tumor mutational burdens (TMB) per sample is also displayed. For clarity, y axis has been cut at 100,000 for TMB. b, Mutational burdens for SBS, DBS, and ID signatures showing positive associations with the tobacco plus alcohol status (n = 265 biologically independent samples). The Kruskal–Wallis test (two sided) was used to test for global

differences. Box-and-whisker plots are in the style of Tukey. The line within the box is plotted at the median, while upper and lower ends indicate 25th and 75th percentiles. Whiskers show 1.5 × interquartile range (IQR), and values outside it are shown as individual data points. Y axes were cut at 1.25 × upper whisker for clarity. Bar plots indicate the frequencies of dichotomized signatures.

570

571 Figure 6. UV-related signatures in head and neck cancer. a, Mutational burdens for mutational 572 signatures related to UV light exposure showing positive associations with the HNC anatomical 573 subsite (n = 265 biologically independent samples). The Kruskal–Wallis test (two sided) was used to test for global differences. Box-and-whisker plots are in the style of Tukey. The line within the box is 574 plotted at the median, while upper and lower ends indicate 25th and 75th percentiles. Whiskers show 575 576 $1.5 \times$ interquartile range (IQR), and values outside it are shown as individual data points. Frequencies 577 of positive samples in each category are indicated in bar plots. b, Single base substitutions (SBS), 578 doublet base substitutions (DBS) and small insertions and deletions (ID) signature burdens in 579 samples positive for UV exposure based on relative SBS7a-c contributions above 10% of relative 580 mutational burdens. Samples are sorted by lip (inner (n=3) or unspecified (n=1)), tongue, and floor of 581 the mouth location within the oral cavity. Positive tobacco and alcohol status are indicated in black. OC, oral cavity; OPC, oropharynx. 582

583

584 Figure 7. Copy number profile and copy number signature analysis in head and neck cancer. a, 585 Copy number (CN) signatures extracted in 242 HNC tumors. The size of each dot represents the proportion of samples presenting the signature, and the color represents the mean relative 586 587 attribution of each signature. b, Copy number spectrum of the newly-identified signature CN_G, 588 defined by a 48 context copy number classification incorporating loss-of-heterozygosity status, total 589 copy number state, and segment length to categorize segments from allele-specific copy number 590 profiles. c, Copy number profiles of HNC cases classified by copy number cluster. Relative signature 591 burdens, CN burden and associated epidemiological characteristics are indicated. The displayed

epidemiological variables show significant differences by CN cluster as per Fisher's exact test and
Benjamini-Hochberg procedure. d, Summary of exposures, driver alterations and CN signatures
associated with each CN cluster. Alluvial diagram depicts the frequency of each etiology in the CN
clusters. WGD, whole-genome duplication; CIN, chromosomal instability; LOH, loss of
heterozygosity.

597 ONLINE METHODS

598 Recruitment of cases and informed consent

599 The IARC/WHO coordinated participant recruitment through the HEADSpAcE and Central European 600 international networks, comprising 13 collaborators from the eight participating countries in Europe 601 and South America (Supplementary Table 14). Inclusion criteria for patients were ≥18 years of age 602 (ranging from 18 to 90 years; with a mean of 60 and standard deviation of 12 years), confirmed 603 diagnosis of primary HNC, and no prior cancer treatment. Informed consent was obtained for all 604 participants. Patients were excluded if they had any condition that could interfere with their ability 605 to provide informed consent or if there were no means of obtaining adequate tissues as per protocol 606 requirements. Ethical approvals were first obtained from each local research ethics committee and 607 federal ethics committee when applicable, as well as from the IARC Ethics Committee.

608

609 Bio-samples and data collection

610 Dedicated standard operating procedures, following guidelines from the International Cancer 611 Genome Consortium (ICGC), were designed by the IARC/WHO to select adequate retrospective case 612 series with complete biological samples and exposure information as described previously^{1,2} 613 (Supplementary Table 14). In brief, for all case series included, anthropometric measures were 614 taken, together with relevant information regarding medical and familial history. All biological 615 samples from retrospective cohorts were collected using rigorous, standardized protocols and 616 fulfilled the required standards of sample collection defined by the IARC/WHO for sequencing and 617 analysis. Retrospective case series were included after examination of their respective recruitment 618 protocols to ensure the availability of necessary biological samples based on standard operating procedures, following guidelines from the ICGC, and also based on the collection of relevant 619 620 exposure history based on a comparison of validated epidemiological questionnaires from each 621 specific region. Comparable smoking and alcohol history was available from all centers, as well as

detailed epidemiological information on oral health, coffee, tea, and mate consumption for specificregions².

624

Potential limitations of using retrospective clinical data collected using different protocols from different populations were addressed by central data harmonization to ensure a comparable group of exposure variables (**Supplementary Table 15**). All patient-related data, as well as clinical, demographical, lifestyle, pathological, and outcome data, were pseudonymized locally using a dedicated alphanumerical identifier system before being transferred to the IARC/WHO central database.

631

632 Expert pathology review

633 Original diagnostic pathology departments provided diagnostic histological details of contributing 634 cases through standard abstract forms, together with a representative hematoxylin-eosin-stained 635 slide of formalin-fixed paraffin-embedded tumor tissues whenever possible. The IARC/WHO 636 centralized the entire pathology workflow and coordinated a centralized digital pathology examination of frozen tumor tissues collected for the study, as well as formalin-fixed paraffin-637 embedded sections when available, via a web-based report approach and a dedicated expert panel, 638 639 following standardized procedures as described previously¹. A minimum of 50% viable tumor cells 640 was required for eligibility for whole-genome sequencing.

641

642 DNA extraction

Extraction of DNA from fresh frozen tumor and matched blood samples was centrally conducted at IARC/WHO. Of the cases that proceeded to the final analysis (*n*=265), germline DNA was extracted from blood samples using previously described protocols and methods¹.

646

647 HPV infection status and genome detection

The HPV infection status was determined by HPV16 E1, E2, E6 and E7 serology. To assess the HPV status in oropharynx cases with missing serologic information (*n*=3), we used two orthogonal NGSbased viral integration tools: Virus intEgration sites through iterative Reference SEquence customization (VERSE) and Fast Viral Integration and Fusion Identification (FastViFi)^{3,4} (Supplementary Table 16; Supplementary Note). VERSE was utilized as part of the VirusFinder2.0 package: https://bioinfo.uth.edu/VirusFinder/ and FastViFi was installed using github: https://github.com/sara-javadzadeh/FastViFi. Default parameters were used for running both tools.

655

656 Whole-genome sequencing

657 A total of 618 patients with HNC were enrolled in the study. Out of those, 315 cases were selected 658 based on pathologic review and DNA quality (tumor and germline), and DNA was received at the 659 Wellcome Sanger Institute for whole genome sequencing. To ensure the tumor and matched normal sample originated from the same individual, Fluidigm SNP genotyping with a custom panel was 660 661 performed. Whole-genome sequencing (150 bp paired-end) was performed on the NovaSeq 6000 662 platform with target coverage of 40× for tumors and 20× for matched normal tissues. All sequencing 663 reads were aligned to the GRCh38 human reference genome using Burrows-Wheeler-MEM (version 664 0.7.16a and version 0.7.17). A standard set of post-sequencing quality criteria was applied for 665 metrics including total coverage, evenness of coverage, and contamination. Cases were excluded if 666 coverage was below 30× for tumors or 15× for normal tissue. For evenness of coverage, the median 667 over mean coverage (MoM) score was calculated, and tumor samples with MoM scores outside the 668 range of values (0.92 - 1.09) which were determined by previous studies to be appropriate were excluded⁵. Conpair⁵ (https://github.com/nygenome/Conpair) was used to detect contamination, and 669 any tumor or normal sample with a value above 3% was excluded⁶. A total of 265 cases passed all 670 671 criteria and were included in subsequent analysis.

672

673 Somatic variant calling

A standard analysis pipeline (https://github.com/cancerit) was used to perform variant calling for 674 copy number variants (ASCAT⁷ and Battenberg⁸, when tumor purity allowed); SNVs (cgpCaVEMan⁹); 675 Indels (cgpPindel¹⁰); and structural rearrangements (BRASS). CaVEMan and BRASS were run using 676 677 the copy number profile and purity values determined from ASCAT when possible (complete 678 pipeline, n=242) or using copy number defaults and an estimate of purity obtained from ASCAT-BATTENBERG when tumor purity was insufficient to determine an accurate copy number profile 679 680 (partial pipeline, n=23). For SNVs, additional filters (ASRD ≥ 140 and CLPM = 0) in addition to the standard PASS filter. To further exclude the possibility of caller-specific artifacts being included in the 681 analysis, a second variant caller, Strelka2, was run for SNVs and IDs^{1,11}, with variants called by both 682 683 the Sanger variant-calling pipeline and Strelka2 included in the final analysis.

684

685 Generation of mutational matrices

686 Mutational matrices for single base substitutions (SBS), doublet base substitutions (DBS), small 687 insertions and deletions (ID), and copy number variants (CNV) were generated using 688 SigProfilerMatrixGenerator (https://github.com/AlexandrovLab/SigProfilerMatrixGenerator) with 689 default options (v1.2.0)¹².

690

691 Mutational signature analysis

692 Multiple methods were used to extract mutational signatures. The primary extractions were performed using SigProfilerExtractor (https://github.com/AlexandrovLab/SigProfilerExtractor) with a 693 694 second method mSigHdp used to validate the de novo mutational signatures extracted (https://github.com/steverozen/mSigHdp)^{13,14}. SigProfilerExtractor v1.1.13 was 695 run using nndsvd_min initialization (NMF_init="nndsvd_min") for 1-20 signature solutions and 500 NMF 696 697 replicates. For SBS mutational signatures were extracted in both SBS1536 and SBS288 contexts. Both 698 results were similar (Supplementary Note) with the SBS1536 results taken forward for the final

699 analysis (Supplementary Table 4). Signatures were extracted using SigProfilerExtractor in the 700 following contexts for other variant types; DBS78 for DBS, ID83 for indels, and CNV48 for copy number variants (Supplementary Tables 5-6,17). The extracted de novo signatures were 701 702 decomposed to COSMIC reference signatures where possible; this step is important as it allows the 703 detection of *de novo* signatures which are made up of multiple reference signatures that have not separated during the extraction process (Supplementary Note). mSigHdp extractions were 704 705 performed using the suggested parameters and using the country of origin to construct the 706 hierarchy for SBS96 and ID83 contexts. A comparison of the SigProfilerExtractor and mSigHdp results 707 can be found in the **Supplementary Note**.

708

709 Attribution of activities of mutational signatures

710 MSA v2.0 (https://gitlab.com/s.senkin/MSA) was used to attribute both de novo and COSMIC 711 mutational signatures15. For COSMIC attributions the panel of signatures included reference 712 signatures identified during the decomposition of mutational signatures in addition to newly 713 extracted signatures which were not decomposed. A conservative approach was used for MSA attributions utilizing the (params.no CI for penalties=false) option for calculation of optimum 714 penalties. Pruned attributions were used for final analysis, where confidence intervals have been 715 716 applied to each attributed mutational signature and any signature activity with a lower confidence 717 limit equal to 0 are removed.

718

719 Driver mutations

Driver mutations in HNC were identified using the following methods. Firstly, dNdS was used to identify genes under positive selection in HNC¹⁶. Results were calculated both for the whole genome (q-value<0.01), and with restricted hypothesis testing (RHT) for a panel of 369 known cancer genes¹⁶. Variants in any gene identified as under positive selection in global dNdS or in the 369-cancer gene panel were considered as potential driver mutations and were then classified as likely drivers if they 725 met any of the following criteria: (i) Truncating mutations in genes annotated as tumor suppressors; 726 (ii) mutations annotated as likely or known oncogenic in MutationMapper; (iii) truncating variants in 727 genes with selection (q value<0.05) for truncating mutations assumed to be tumor suppressors and 728 thus likely drivers; (iv) missense variants in all genes under positive selection and with dN/dS ratios 729 for missense mutations above five (assuming four of every five missense mutations are drivers) 730 labeled as likely drivers; or (v) in-frame indels in genes under significant positive selection for in-731 frame indels. The Cancer Gene Census (https://cancer.sanger.ac.uk/census) and the Cancer Genome 732 Interpreter tool (https://www.cancergenomeinterpreter.org) were used to annotate potential 733 drivers with the mode of action. Missense mutations were assessed using the MutationMapper tool 734 (http://www.cbioportal.org/mutation_mapper).

735

736 Copy number profile

The copy number profiles were investigated in a subset of cases with available copy number data (complete pipeline, *n*=242). Unsupervised clustering analysis of the copy number counts was performed using Euclidean distance and Ward's agglomerative procedure. Driver copy number alterations were defined as cancer-related alterations in the COSMIC cancer gene census as follows^{17,18}: (1) homozygous deletion (CN = (0, 0)) of genes listed as deleted in COSMIC; and (2) amplification (CN > 2 × ploidy + 1) of genes listed as amplified (A) in COSMIC or *PIK3CA* gains, a commonly-reported HNC alteration^{19,20}.

744

745 Evolutionary analysis

MutationTimeR²¹ was run to annotate mutations as either early clonal, late clonal, subclonal, or NA clonal (meaning clonality could not be assigned). Samples with at least 256 early clonal mutations and at least 256 late clonal mutations were retained (*n*=173), and the early and late clonal mutations for these samples were split into individual VCF files. SigProfilerAssignment²² was run on the resulting VCF files to identify the mutational processes active in the early clonal and late clonal

751 mutations for each sample. Differences between the early and late relative activity of each 752 mutational signature were assessed using a Wilcoxon signed-rank test, and p-values were corrected 753 across signatures using the Benjamini-Hochberg Procedure (q-value).

754

755 Regressions and associations with signatures

Signature attributions were dichotomized into presence and absence using confidence intervals, with presence defined as both lower and upper limits being positive, and absence as the lower limit being zero. If a signature was present in at least 75% of cases (SBS1, SBS2, SBS13, SBS18, SBS_I, ID1, and ID2), it was dichotomized into above and below the median of attributed mutation counts. The binary attributions served as dependent variables in logistic regressions, and relevant risk factors were used as factorized independent variables. Regressions with variables presenting data separation were performed using Firth's penalized logistic regression.

763

For SBS, DBS, and ID mutation burden analyses, cases defined as hypermutators (mutation burdens more than 1.5 IQR above Q3) were excluded and associations with epidemiological factors were assessed using linear regression analysis.

767

Regressions with HNC incidence (age-standardized rates) were performed as linear regressions with signature attributions (those present in at least 75% of cases) with confidence intervals not consistent with zero. Signatures present in less than 75% of cases were dichotomized into presence and absence as previously mentioned and analyzed using the logistic regressions. Age-standardized rates were obtained from Global Cancer Observatory (GLOBOCAN 2022)²³. Regressions were performed on a sample basis.

- To adjust for confounding factors, sex, age of diagnosis, subsite, region, tobacco, and alcohol status
- were added as covariates in all regressions. The region variable was categorized as Europe and South
- America. The Bonferroni method was used to test for significant p-values.
- 778

779 DATA AVAILABILITY

- 780 Whole genome sequencing data and patient metadata are deposited in the European Genome-
- 781 phenome Archive (EGA) associated with study EGAS00001005450. Mutational catalogs for the
- 782 PCAWG dataset can be accessed at https://dcc.icgc.org/releases/PCAWG. All other data is provided
- in the accompanying Supplementary Tables.
- 784

785 CODE AVAILABILITY

- All algorithms used for data analysis are publicly available with repositories noted within the
- respective method sections and in the accompanying reporting summary. Code used for regression
- analysis and figures is available at https://gitlab.com/mutographs-hnc.

789 METHODS REFERENCES

- Moody, S. *et al.* Mutational signatures in esophageal squamous cell carcinoma from eight
 countries with varying incidence. *Nat Genet* 53, 1553–1563 (2021).
- Perdomo, S. *et al.* The Mutographs biorepository: A unique genomic resource to study
 cancer around the world. *Cell Genomics* 100500 (2024).
- Javadzadeh, S. *et al.* FastViFi: Fast and accurate detection of (Hybrid) Viral DNA and RNA.
 NAR Genom Bioinform 4, (2022).
- Wang, Q., Jia, P. & Zhao, Z. VERSE: A novel approach to detect virus integration in host
 genomes through reference genome customization. *Genome Med* 7, 1–9 (2015).
- 798 5. Whalley, J. P. *et al.* Framework for quality assessment of whole genome cancer sequences.
 799 *Nat Commun* **11**, (2020).
- 800 6. Bergmann, E. A., Chen, B. J., Arora, K., Vacic, V. & Zody, M. C. Conpair: concordance and 801 contamination estimator for matched tumor–normal pairs. *Bioinformatics* **32**, 3196 (2016).
- 802 7. Van Loo, P. *et al.* Allele-specific copy number analysis of tumors. *Proc Natl Acad Sci U S A* 803 **107**, 16910–16915 (2010).
- 804 8. Nik-Zainal, S. *et al.* The life history of 21 breast cancers. *Cell* **149**, 994–1007 (2012).
- 9. Jones, D. *et al.* cgpCaVEManWrapper: Simple Execution of CaVEMan in Order to Detect
 Somatic Single Nucleotide Variants in NGS Data. *Curr Protoc Bioinformatics* 56, 15.10.115.10.18 (2016).
- Raine, K. M. *et al.* cgpPindel: Identifying Somatically Acquired Insertion and Deletion Events
 from Paired End Sequencing. *Curr Protoc Bioinformatics* 52, 15.7.1 (2015).
- 810 11. Kim, S. *et al.* Strelka2: fast and accurate calling of germline and somatic variants. *Nature*811 *Methods 2018 15:8* 15, 591–594 (2018).
- 812 12. Bergstrom, E. N. *et al.* SigProfilerMatrixGenerator: a tool for visualizing and exploring
 813 patterns of small mutational events. *BMC Genomics* 20, (2019).

- 13. Islam, S. M. A. *et al.* Uncovering novel mutational signatures by de novo extraction with
- 815 SigProfilerExtractor. *Cell Genomics* **2**, 100179 (2022).
- 816 14. Liu, M., Wu, Y., Jiang, N., Boot, A. & Rozen, S. G. mSigHdp: hierarchical Dirichlet process
- 817 mixture modeling for mutational signature discovery. *NAR Genom Bioinform* **5**, (2023).
- 818 15. Senkin, S. MSA: reproducible mutational signature attribution with confidence based on
 819 simulations. *BMC Bioinformatics* 22, 1–11 (2021).
- 820 16. Martincorena, I. *et al.* Universal Patterns of Selection in Cancer and Somatic Tissues. *Cell*821 **171**, 1029-1041.e21 (2017).
- 822 17. Steele, C. D. *et al.* Signatures of copy number alterations in human cancer. *Nature 2022* 823 606:7916 606, 984–991 (2022).
- 18. Tate, J. G. *et al.* COSMIC: The Catalogue Of Somatic Mutations In Cancer. *Nucleic Acids Res*47, D941–D947 (2019).
- Sayáns, M. P. *et al.* Comprehensive Genomic Review of TCGA Head and Neck Squamous Cell
 Carcinomas (HNSCC). *Journal of Clinical Medicine 2019, Vol. 8, Page 1896* 8, 1896 (2019).
- Leemans, C. R., Snijders, P. J. F. & Brakenhoff, R. H. The molecular landscape of head and
 neck cancer. *Nat Rev Cancer* 18, 269–282 (2018).
- 830 21. Gerstung, M. *et al.* The evolutionary history of 2,658 cancers. *Nature 2020 578:7793* 578,
 831 122–128 (2020).
- Díaz-Gay, M. *et al.* Assigning mutational signatures to individual samples and individual
 somatic mutations with SigProfilerAssignment. *bioRxiv* (2023)
 doi:10.1101/2023.07.10.548264.
- Sung, H. *et al.* Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality
 worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* **71**, 209–249 (2021).
- 837
- 838
- 839

840 ACKNOWLEDGEMENTS

The authors would like to thank Laura O'Neill, Kirsty Roberts, Katie Smith, Siobhan Austin-Guest and the staff of Sequencing Operations at the Wellcome Sanger Institute for their contribution. We are grateful for the support provided by the IARC General Services, including the Laboratory Services and Biobank team led by Z. Kozlakidis, the Section of Support to Research overseen by T. Landesz. The authors would like to thank Maggie Blanks and Mimi McCord for useful discussions. The authors would also like to thank all the patients and their families involved in this study.

847

848 FUNDING

849 This work was delivered as part of the Mutographs team supported by the Cancer Grand Challenges 850 partnership funded by Cancer Research UK (C98/A24032). Work at the Wellcome Sanger Institute 851 was also supported by the Wellcome Trust (grants 206194 and 220540/Z/20/A), and work at the 852 IARC/WHO was supported by regular budget funding. This work was also supported by the US 853 National Institute of Health grants R01ES032547-01, R01CA269919-01, and 1U01CA290479-01 to 854 L.B.A. as well as by L.B.A.'s Packard Fellowship for Science and Engineering. The research performed in L.B.A.'s lab was supported by UC San Diego Sanford Stem Cell Institute. The head and neck cancer 855 856 collection received funding from the European Union's Horizon 2020 research and innovation 857 program under grant no. 825771 and the São Paulo Research Foundation, FAPESP 2018/26297-3. J.P. 858 and F.G. were partially supported by Italian Ministry of Health - Ricerca Corrente. The funders had 859 no roles in study design, data collection and analysis, decision to publish, or preparation of the 860 manuscript.

861

862 CONTRIBUTIONS

The study was conceived and designed by S.P. and P.B., and supervised by S.P., P.B., M.R.S., and L.B.A. Analysis of data was performed by L.T., S.M., A.C.D.C., M.K., S.C., S.S., T.C., R.C.C.P., J.R.A., V.G., A.A., E.N.B., R.V., J.W., S.F., M.D., D.J., and J.T. Pathology review was carried out by B.A. Sample

866	manipulation was carried out by P.C., C.Carreira, and C.L. Patient and sample recruitment was led or
867	facilitated by F.R.P., L.P.K., J.P., F.G., J.C.D.C., P.L., A.L., M.V., D.M., I.N.M., L.M.A., R.R., J.R.V.P.,
868	S.V.V.Z., I.H., M.P.C., C.Canova, E.F., and P.A.R. Data generation was performed by J.W., S.F., and C.L.
869	Scientific project management was carried out by A.C.D.C. and L.H. L.T. L.T. and S.M. contributed and
870	were responsible for overall scientific coordination. The manuscript was written by L.T., S.M.,
871	A.C.D.C., L.B.A., P.B., M.R.S., and S.P., with contributions from all other authors.

872

873 COMPETING INTERESTS

L.B.A. is a co-founder, CSO, scientific advisory member, and consultant for io9, has equity and 874 875 receives income. The terms of this arrangement have been reviewed and approved by the University 876 of California, San Diego in accordance with its conflict of interest policies. L.B.A. is also a compensated member of the scientific advisory board of Inocras. L.B.A.'s spouse is an employee of 877 878 Biotheranostics. E.N.B. and L.B.A. declare U.S. provisional patent applications filed with UCSD with 879 serial numbers 63/289,601; 63/269,033; and 63/483,237. A.A. and L.B.A. declare U.S. provisional 880 patent application filed with UCSD with serial number 63/366,392. L.B.A. also declares U.S. provisional application 63/412,835 and international application PCT/US2023/010679 filed with 881 882 UCSD. L.B.A. is also an inventor of a US Patent 10,776,718 for source identification by non-negative 883 matrix factorization. All other authors declare that they have no competing interests.

884

885 **DISCLAIMER**

886 Where authors are identified as personnel of the International Agency for Research on Cancer/ 887 World Health Organization, the authors alone are responsible for the views expressed in this article 888 and they do not necessarily represent the decisions, policy or views of the International Agency for 889 Research on Cancer / World Health Organization.

890

891 CORRESPONDING AUTHOR

892 Correspondence to Sandra Perdomo.

893 EXTENDED DATA FIGURE LEGENDS

894 Extended Data Figure 1. Mutational burdens in HNC. a-c, Mutational burdens for single base 895 substitutions (SBS), doublet base substitutions (DBS) and small insertions and deletions (ID) burdens 896 by anatomical subsite (a), smoking status (b) and country (c). Panel b depicts the mutation burdens 897 by smoking status in the whole HNC dataset (left) and across anatomical subsites (right). Kruskal-898 Wallis test (two sided) was used to test for global differences. Box-and-whisker plots are in the style 899 of Tukey. The line within the box is plotted at the median, while upper and lower ends indicate 25th 900 and 75th percentiles. Whiskers show 1.5 × interguartile range (IQR), and values outside it are shown 901 as individual data points. Hypermutators defined as samples with mutation burdens above 100,000 902 for SBS (n=4), 6,000 for DBS (n=1) and 5,000 for ID (n=1) were removed from the analysis. OC, oral 903 cavity; OPC, oropharynx; HPX, hypopharynx.

904

905 **Extended Data Figure 2. SBS signature decomposition.** Decomposed SBS signatures, including 906 reference COSMIC signatures and *de novo* signatures not decomposed into COSMIC reference 907 signatures.

908

Extended Data Figure 3. DBS and ID signature decomposition. Decomposed DBS (a) and ID (b)
 signatures, including reference COSMIC signatures and *de novo* signatures not decomposed into
 COSMIC reference signatures.

912

Extended data Figure 4. Evolutionary analysis of mutational signatures and driver mutations in HNC. a, Comparison of mutational signatures between early and late clonal mutations in HNC (*n*=173). b, Relative activities of SBS_I in early and late clonal mutations across anatomical subsites. Lines show the change in relative activity between the early and late clonal mutations within a positive sample. Colored lines represent an activity change of more than 6% (blue indicates higher in the clonal early mutations; orange indicates higher in the clonal late mutations). Bar plots show the

distribution of activities in samples where the signature was present in the early and/or late clonal
mutations; the number of positive samples is represented in the title of each plot. Black bars
indicate one standard deviation away from the mean. Significance was assessed using a two-sided
Wilcoxon signed-rank test, and p-values were corrected using the Benjamini-Hochberg Procedure (qvalue). OC, oral cavity; OPC, oropharynx; LYX, larynx; HPX, hypopharynx.

924

925 Extended Data Figure 5. Association of tobacco-related mutational signatures with anatomical 926 subsites and tobacco status. a, Mutational burdens for tobacco-related mutational signatures by anatomical subsite (n = 265 biologically independent samples). **b**, Mutational burdens for mutational 927 928 signatures showing significant negative associations with tobacco consumption. The Kruskal–Wallis 929 test (two sided) was used to test for global differences. Box-and-whisker plots are in the style of 930 Tukey. The line within the box is plotted at the median, while upper and lower ends indicate 25th and 931 75th percentiles. Whiskers show 1.5 × interquartile range (IQR), and values outside it are shown as 932 individual data points. Y axes were cut at 1.25 × upper whisker for clarity. Bar plots indicate the 933 frequencies of dichotomized signaturesOC, oral cavity; OPC, oropharynx.

934

935 Extended Data Figure 6. Driver alterations and driver mutation spectra in HNC. a, Driver mutations 936 in HNC samples (n=265) sorted by tobacco and alcohol status. Genes mutated in more than 2% of 937 the cases are shown. b, Driver mutations and copy number events in HNC samples with available 938 copy number data (n=242). Only driver genes with both copy number gains and losses are included. 939 Top, tumor mutational burden (TMB) per sample. Middle, presence of mutations per sample. 940 Bottom, epidemiological characteristics. Frequency of mutations in the HNC dataset and q values 941 from two-sided Fisher's exact text are displayed. c, SBS96-mutation spectrum of driver mutations in 942 smokers and non-smoker HNC cases and percentage of driver mutations occurring in C>A contexts.

943

944 Extended Data Figure 7. Mutational signature and driver spectra of oropharynx HNC cases by HPV

945 status. a, Average relative attributions of SBS signatures by human papillomavirus (HPV) positivity 946 and tobacco status in oropharynx (OPC) cancers. **b**, Driver mutations in OPC HNC samples (n=46) 947 sorted by HPV and tobacco status. Genes mutated in more than 2% of the samples are shown. c, 948 Driver mutations and copy number events in OPC HNC samples with available copy number data 949 (n=44). Only driver genes with copy number gains and losses are included. Top, tumor mutational 950 burden (TMB) per sample. Middle, presence of mutations per sample. Bottom, HPV status and 951 tobacco smoking. Frequency of mutations in the HNC dataset and q values from two-sided Fisher's 952 exact text are displayed.

953

Extended Data Figure 8. Copy number profile of head and neck cancer clusters. a, Genome-wide segments showing major and minor allele counts in 10 randomly picked samples per copy number (CN) cluster. b, Ploidy, CN burden, and burden of CN gains, losses, and CN neutral LOH (NLOH) across clusters (n = 242 biologically independent samples). The Kruskal–Wallis test (two sided) was used to test for global differences. Box-and-whisker plots are in the style of Tukey. The line within the box is plotted at the median, while upper and lower ends indicate 25th and 75th percentiles. Whiskers show 1.5 × interquartile range (IQR), and values outside it are shown as individual data points.

961

962 Extended Data Figure 9. Copy number signature decomposition. Decomposed copy number
 963 signatures including reference COSMIC signatures and *de novo* signatures not decomposed into
 964 COSMIC reference signatures.

965

Extended Data Figure 10. Copy number signature enrichment by HNC clusters and driver profile. ab, Signature burdens for copy number signatures by copy number cluster showing associations with
cluster D (a) and cluster P (b). c, Signature burdens for CN5 and CN_G signatures in copy number
clusters D and P. The Kruskal–Wallis test (two sided) was used to test for global differences. Box-and-

970	whisker plots are in the style of Tukey. The line within the box is plotted at the median, while upper
971	and lower ends indicate 25 th and 75 th percentiles. Whiskers show 1.5 × interquartile range (IQR), and
972	values outside it are shown as individual data points. Y axis were cut at 1.25 \times upper whisker for
973	clarity. Bar plots indicate the frequencies of dichotomized signatures. d, Associations between copy
974	number clusters or signatures and driver alterations. Effect size (log2(OR), color), and significance
975	level (-log2(q), size) from two-sided Fisher's exact tests, corrected using the Benjamini-Hochberg
976	Procedure, are displayed. Only significant associations are shown (q < 0.05).

977 SUPPLEMENTARY TABLE AND FIGURE LEGENDS

- 978 Supplementary Table 1. Clinical and epidemiological characteristics of the HNC dataset.
- 979 Supplementary Table 2. Mutation burdens per sample.
- 980 Supplementary Table 3. Associations of HNC risk factors with and mutational burden.
- 981 Supplementary Table 4. SBS *de novo* signatures extracted from 265 HNC cases.
- 982 Supplementary Table 5. DBS *de novo* signatures extracted from 265 HNC cases.
- 983 Supplementary Table 6. ID de novo signatures extracted from 265 HNC cases.
- 984 Supplementary Table 7. Decomposition of *de novo* mutational signatures to COSMIC reference
- 985 signatures.
- 986 Supplementary Table 8. Activities of *de novo* mutational signatures in HNC cases.
- 987 Supplementary Table 9. Activities of decomposed COSMIC signatures in HNC cases.
- 988 Supplementary Table 10. Associations of HNC risk factors with COSMIC mutational signatures.
- 989 Supplementary Table 11. Likely driver mutations identified in HNC.
- 990 Supplementary Table 12. Likely driver copy number alterations identified in HNC.
- 991 Supplementary Table 13. Associations of HNC risk factors with copy number clusters.
- 992 Supplementary Table 14. Details of individual case collections.
- 993 Supplementary Table 15. Details of data harmonization for HNC risk factors.
- 994 Supplementary Table 16. Details of HPV16 assessment in oropharynx cases.
- 995 Supplementary Table 17. CNV48 de novo signatures extracted from 242 HNC cases.
- 996

997 Supplementary Figure 1. Correlations amongst mutational signatures. Pearson correlation
 998 coefficients for each significant comparison are indicated.

999

Supplementary Figure 2. Association of tobacco-related signatures and HNC incidence. Association
 between tobacco-related signatures with age-standardized rate (ASR) incidence. Number of
 mutations attributed to SBS4, SBS92, SBS_I, DBS2, DBS6, and ID3 mutational signatures against ASR

1003	of HNC per country, sex, and subsite. The p-values shown are for ASR variable in regressions across
1004	all cases, adjusted for age. The frequency of the signatures and number of cases per group are
1005	indicated.

1006

Supplementary Figure 3. Hierarchical clustering of copy number data. Unsupervised hierarchical clustering analysis of copy number counts in the HNC cohort (*n*=242) using Euclidean distance and Ward's agglomerative procedure. Two main clusters (diploid (D) and polyploid (P)) were obtained, which further subdivided into four groups. Right panel shows the copy number frequency in the HNC cohort.

1012

Supplementary Figure 4. Single base substitution signatures extracted by SigProfilerExtractor. All single base substitution (SBS) de novo signatures extracted in SBS-1536 (15 signatures) and SBS-288 (14 signatures) format, shown side by side for comparison. Equivalent signatures where not extracted in SBS-288 format for SBS1536J. For clarity, the signatures context is retained in the

1017 signature names in this figure.

1018

Supplementary Figure 5. Single base substitution mutational signatures extracted by mSigHdp.
 Fifteen single bases substitution (SBS) de novo signatures extracted by mSigHdp.

1021

1022 Supplementary Figure 6. Small insertion and deletion mutational signatures extracted by mSigHdp.

1023 Eight small insertion and deletion (ID) de novo signatures extracted by mSigHdp.

1024

1025 Supplementary Figure 7. Mutational spectra supporting non-decomposed mutational signatures.

1026 Individual mutational spectra are shown for cases which support the existence of non-decomposed

signatures SBS_I (SBS1536I) (a), SBS_L (SBS1536_L) (b) and DBS_D (DBS78D) (c).

Supplementary Figure 8. Principal component analysis of HNC SBS96 mutation counts and signature attributions. Principal component analysis (PCA) performed on 256 cases of HNC on relative SBS96 mutation counts colored by **a**, anatomic site, **b**, tobacco status, and **c**, relative proportion of each mutation class (C>A, C>G, C>T, T>A, T>C, T>G). Circled on the anatomic site/ C>T plot is a subset of oral cavity HNC which have UV exposure. PCA performed on 256 cases of HNC on relative signature attributions colored by **d**, anatomic site, **e**, tobacco status and **f**, relative attributions of tobacco associated signatures SBS4, SBS92 and SBS_I.

1036

Supplementary Figure 9. UV exposure in HNC. Support for the presence of UV in HNC of the oral cavity showing **a**, representative HNC oral cavity mutational specter which is consistent with representative melanoma mutational spectra from the PCAWG cohort and **b**, correlation between mutational signatures known to be associated with UV exposure in HNC. Correlation coefficients for each significant comparison are indicated.

1042

1043 Supplementary Figure 10. Attribution of HNC mutational signatures in external datasets. 1044 Attribution of HNC mutational signatures SBS_I (a) and SBS_L (b) in external datasets. The Kruskal-1045 Wallis test (two sided) was used to test for global differences. Box-and-whisker plots are in the style 1046 of Tukey. The line within the box is plotted at the median, while upper and lower ends indicate 25th 1047 and 75th percentiles. Whiskers show 1.5 × interquartile range (IQR), and values outside it are shown 1048 as individual data points. Overall mutational signature landscape in in the external datasets was 1049 similar (c) with the presence of additional individual mutational spectra (d) supporting the existence 1050 of SBS I.

1051

Supplementary Figure 11. Correlations amongst copy number signatures. Pearson correlation
 coefficients for each significant comparison are indicated.

1054

Supplementary Figure 12. Predicted ancestry in HNC. a, Scatter plots of principal components PC1 and PC2 based on genotype data showing the genetic structure of the HNC cohort across different countries of origin. **b,** Ancestry admixture in the HNC cohort. **c,** Probability of African ancestry by country.

1059

Supplementary Figure 13. Clustered mutations in HNC. a-b, Distribution of clustered mutations in HNC by tobacco status (a) and anatomical subsite (b) ordered by median tumor mutational burden (TMB). Each dot represents a single tumor. The clustered mutation ratio is calculated as the fraction of clustered mutations compared to the total number of mutations in a given sample. Each clustered event is subclassified and summarized as the proportion of mutations per country associated with a double-base substitution event, an omikli event, or as a kataegis event.

1066

1067 **Supplementary Figure 14. Evolutionary analysis of driver mutations in HNC.** Relative frequency of 1068 driver mutations across early clonal and late clonal/subclonal stages, for the most common driver 1069 genes in HNC (*n*=173).

1070

Supplementary Figure 15. Human papillomavirus integration in HNC tumors. a, Frequency of 1071 1072 HPV16 integrations in genic and non-genic regions. b, Integration sites detected in chromosomal, 1073 cytoband, and genic regions. Rows represent samples positive for viral integration. The number of 1074 integrations per site and sample is depicted. Only four samples presented integrations in genic 1075 regions. c-d, Circos plots representing viral integration sites, structural variations (SV) and copy 1076 number (CN) alterations in tumor genomes presenting HPV16 integration. HPV integrations (in 1077 yellow) are depicted in the outermost ring, CN in the inner ring, and SV events in the center. Specific 1078 SV and CN alterations (CNA) surrounding the sites of integration (dotted lines) are shown for three 1079 samples (d).

1080

1081 Supplementary Figure 16. Associations between germline ADH1B and ADH7 variant genotype and 1082 alcohol related mutational signatures. ADH1B rs1229984 and ADH7 rs1573496 germline variant 1083 genotypes for signatures SBS16 (a), DBS4 (b) and ID11 (c) (n=265 biologically independent samples). 1084 Mutated samples correspond to those with at least one alternative allele. The Kruskal–Wallis test 1085 (two sided) was used to test for global differences. Box-and-whisker plots are in the style of Tukey. 1086 The line within the box is plotted at the median, while upper and lower ends indicate 25th and 75th 1087 percentiles. Whiskers show 1.5 × interquartile range (IQR), and values outside it are shown as 1088 individual data points. Y axes were cut at 1.25 × upper whisker for clarity. Bar plots indicate the 1089 frequencies of dichotomized signatures.

0

00

a medRxiv preprint doi: https://doi.org/10.1101/2024.04.15.24305006; this version posted April 17, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization / International Agency for Research on Cancer concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate borderlines for which there may not yet be full agreement. Cancer TODAY | IARC https://gco.iarc.who.int/today Data version: Globocan 2022 - 08.02.2024 © All Rights Reserved 2024 International Agency for Research on Cancer World Health Organization



а

С







0

С

Larynx smoker Oral cavity smoker

















d

а medRxiv preprint doi: https://doi.org/10.1101/2024.04.15.24305006; this verging posted April 17, 2024. The copyright holder for thip organized (which was not certified by peer review) is the author/funder owno has granted med Rxiv, a license to display the preprint in perpetuity. 100000 4000 1500 75000 Mutation burden Mutation burden Mutation burden 3000 1000 50000 2000 500 25000 1000 0 0 0 080 oC OPC °C 09^C 60 Lary 2art HNPOONS rhypophai . 8 HYPOPhi subsite subsite subsite b С SBS burden SBS burden al-Wallis, p = 1.13e-07 OPC HPX ос Larynx Kruskal-Wallis, p = 0.48 100000 100000 p = 0.023 p = 0.062 p = 0.138 p =1.28E-0 75000 75000 Mutation burden Mutation burden 50000 50000 25000 25000 0 0 Junentemot Clech Republ EX-SMOX EX-Smot Current sm Current-sm Current sm EX-SM EX-sm Non-sm Slovat NON 205 4000 ò country tobacco DBS burden DBS burden 2000 Kruskal-Wallis, p = 1.62e-18 oc OPC HPX Larynx Kruskal-Wallis, p = 0.073 p =5.61e-09 p = 0.87 p =4.51E-06 p = 0.001 1500 1500 Mutation burden 2000 2000 2000 Mutation burden 1000 500 0 0 EX-STOKET Current shoket EX-smoker Clech Republic smoker ourent snok ounent smoke ourent snot Eternot EX-Smot Slovat R.01 S 400 2 CUT tobacco country ID burden ID burden al-Wallis, p = 9.54e-09 oc OPC HPX Larynx Kruskal-Wallis, p = 0.72 p =1.86E-0 4000 p = 0.0492 p =0.0022 p = 0.419 4000 Mutation burden Mutation burden 3000 3000 2000 2000 1000 1000 Lesting Stokes of the Current Stokes Surent Store or 0 0 smoker Cleon Republi Current shot colombia Current-smol EXSMON Non-smot EX-smot Current sm EX-smot Argentin Greec Slovat

Non-st

tobacco

405

Hori

Rom

country

ses (which was not certified	by peer review) is the author/fund All rights reserved.	05006; this versic larywho has grant No reuse allowed	n posted April 17 , 262 ed n 888 Rxiv a license without permission.	to display the preprint in perpet	preprint Sig. Mutations: 416,151/7.8%
		10 FX 00 FX 00 FX 00 F			
C>A C>G	C>T T>A T>C s	T>G	C>A C SBS5	>G C>T T>A	T>C T>G Sig. Mutations: 1,660,858/31.2%
	nt and bran				
C>A C>G	C>T T>A T>C	T>G Sig. Mutations: 190,626/3.6%	C>A C	>G C>T T>A	T>C T>G Sig. Mutations: 384,774/7.2%
			29 20 20 20 20 20 20 20 20 20 20 20 20 20		
сорание и на		T>G		>G C>T T>A	T>C T>G
SBS7c		Sig. Mutations: 37,906/0.7%	SBS12		Sig. Mutations: 0/0.0%
		2000 2001 2002 2002 2002 2002 2002 2002			
C>A C>G SBS13	C>T T>A T>C	T>G	C>A C	>G C>T T>A	T>C T>G Sig. Mutations: 13,488/0.3%
		2000 2000 2004 2004 2004 2004 2004 2004			
SBS16	C>T T>A T>C	T>G Sig. Mutations: 7,368/0.1%	C>A C	>G C>T T>A	T>C T>G Sig. Mutations: 6,143/0.1%
			2720 2720 2720 2720 2720 2720 2720 2720		
C>A C>G	C>T T>A T>C	T>G Sig. Mutations: 29,735/0.6%	C>A C	>G C>T T>A	T>C T>G Sig. Mutations: 217,757/4.1%
11 DN- 11 DN-			G 1280 G 1280 S 129 S		
	C>T T>A T>C	T>G		SG C>T T>A	T>C T>G
			B 20202A		- @
C>A C>G	C>T T>A T>C	т>G		>G C>T T>A	
SBS92		Sig. Mutations: 205,393/3.9%	By Data SBS93		Sig. Mutations: 12,581/0.2%
C>A C>G	C>T T>A T>C	T>G Sig. Mutations: 426,087/8.0%	C>A C		T>C T>G Sig. Mutations: 63,180/1.2%
	իսյիսի, իրես իրես ներ				difference in the second

а	medRxiv preprint doi: https://doi.org/10.1101/2024.04.15.24305006; this versic	on posted April 17, 2024. The copyright holder for this preprint
:	(which was not contified by peer review) is the author/funder-who has grant All rights reserved. No reuse allowed	ted medRwiv a licensector displayin he proprint drup perpetuityrc>nn to>nn tt>nn without permission.
	Sig. Mutations: 19,027/87.7%	BBSZ Sig. Hutations: 10,447/32.046
:		
		22222222222222222222222222222222222222
	AC>NN AT>NN CC>NN CG>NN CT>NN GC>NN TA>NN TC>NN TG>NN TT>NN	AC>NN AT>NN CC>NN CG>NN CT>NN GC>NN TA>NN TC>NN TG>NN TT>NN
	sig. Mutations: 6,07/JJ.3.276	DBS6 Sig. Putatuons: 3,240/10.449
	8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	8 000092944400092844493944449394444895444442354440364430644403698444036988444036988444036988444036988444035888
	AC>NN AT>NN CC>NN CG>NN CT>NN GC>NN TA>NN TC>NN TG>NN TT>NN	
	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	
b	>1bp Deletion at Repeats >1bp Insertion at Repeats Microhomology	>1bp Deletion at Repeats >1bp Insertion at Repeats Microhomology
	Ibp Deletion 1bp Ibp Insertion (Deletion Length) (Insertion Length) (Deletion Length) 112% C T 2 3 4 5+ 2 3 4 5+ 112% C T 2 3 4 5+ 2 3 4 5+	Ibp Deletion 1bp Insertion (Deletion Length) (Insertion Length) (Deletion Length) 104% C T C T 2 3 4 5+ 3 5+ 3
:	9 5ig. Mutations: 104,816,40.3%	78%
		6 52%
	1234584345042340542345623456234562345554345543455423450642340542340542340542340542340542345523455	1 2 3 4 5 % 2 3 4 5 6 4 2 3 4 6 4 2 3 4 5 4 2 3 4 5 5 4 5 5 4 3 5 5 4 3 5 5 4 3 6 4 2 3 4 6 4 4 2 3 4 6 4 4 2 3 4 6 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
	1bp Deletion 1bp Insertion 21bp Deletion tar Repeats >1bp Insertion at Repeats Microhomology 1bp Deletion 1bp Insertion 1bp Insertion at Repeats (Insertion tar Repeats) Microhomology 1bp Deletion 1bp Insertion 1bp Insertion 1bp Insertion 1bp Insertion 1bp Insertion 1bp Deletion 1bp Insertion 1bp Insertion 1bp Insertion 1bp Insertion 1bp Insertion 1bp Deletion 1bp Insertion 1bp Insertion 1bp Insertion 1bp Insertion 1bp Insertion	Solution Subscription Subscription Subscription Microhomology (Disection Length) Microhomology (Disection Length) Microhomology (Disection Length) C T C T 2 3 4 5+ 2 3 4 5+ 2 3 4 5+ 2 3 4 5+ 2 3 4 5+ 2 3 4 5+ 2 3 4 5+ 2 3 4 5+ 2 3 4 5+ 2 3 4 5+ 2 3 4 5+ 2 3 4 5+ 2 3 4 5+ 2 3 4 5+ 2 3 4 5+ 2 3 4 5+ 2 3 5+ 2 3 5+ 2 3 4 5+ 2 3 4 5+ 2 3 4 5+ 2 3 4 5+ 2
	28% 103 Sig. Mutations: 65,619/25.4% # 21%	285 D4 Sig. Mutations: 0,0.0%
	ے تو ہے۔ وی دس	A 5
	2740	2%
	12345863460423406423458234582345823458234582345823405423405423405423405423405423405423405423405423405423405423405423405423405423405420540540540540540540540540540540540540540	7 1 2 3 4 5 # 2
	>1bp Deletion at Repeats >1bp Insertion at Repeats (Deletion at Repeats Microhomology (Deletion Length) (Deletion Length)	>1bp Deletion at Repeats >1bp Insertion at Repeats Microhomology 1bn Deletion 1bn Insertion (Deletion Length) (Deletion Length)
	16% C T C T 2 3 4 5+ 2 3 4 5+ 2 3 4 5+ 105 Sign Mutations: 18,305/7.1%	200 C C C Z 3 4 5+ 2 3 4 5+ 2 3 4 5+ 2 3 4 5+ 2 3 4 5+ 2 3 4 5+ 54 5+ 510 50 510 510 510 510 510 510 510 510
		89
	Homopolymer Length Number of Repeat Units Number of Repeat Units Number of Repeat Units Microhomology Length	Homopolymer LengtiHomopolymer Length Number of Repeat Units Number of Repeat Units Microhomology Length
	Signal Control Contron Control Control Control Control Control Control Contro	Subj Subj <th< th=""></th<>
		B33%
	C	5 822% E
	1 2 3 4 5 56 2 3 4 564 2 3 4 564 2 3 4 56 2 3 4 5 56 2 3 4 5 56 2 3 4 564 2 3 4 664 2 3 4 664 2 3 4 664 2 3 4 56 2 1 2 31 2 31 2 31 4 5+ Homopolymer LengtHomopolymer Length Number of Repeat Units Number of Repeat Units Microhomology Length	1 2 3 4 5 % 4 3 6 4 2 3 4 5 4 2 3 4 5 % 2 3 4 5 % 2 3 4 5 % 2 3 4 5 % 2 3 4 5 % 2 3 4 6 4 2 3 4 6 4 2 3 4 6 4 2 3 4 5 % 2 1 2 3 4 5 % 2 1 2 3 4 5 % 2 1 2 3 4 5 % 2 1 2 3 4 5 % 2 1 2 3 4 5 % 2 1 2 3 4 5 % 2 1 2 3 4 5 % 2 1 2 3 4 5 % 2 1 2 3 4 5 % 2 1 2 3 4 5 % 2 % 2 % 2 % 2 % 2 % 2 % 2 % 2 % 2 %
	Solution Solution at Repeats Solution at Repeats Solution at Repeats Microhomology 1bp Deletion 1bp Insertion (Deletion Length) (Insertion Length) (Deletion Length)	1bp Deletion 1bp Insertion >1bp Deletion at Repeats (Deletion Length) >1bp Insertion at Repeats (Insertion Length) Microhomology (Deletion Length)
	C C T Z 3 4 5+ Z 3 4 </th <th>200 C C Z Z 3 4 5+ Z 3 5+ Z 3 4 5+ Z 3 5+ Z 3</th>	200 C C Z Z 3 4 5+ Z 3 5+ Z 3 4 5+ Z 3
	1,2 3 4 5 86 2, 3 5 86 2 3 4 86 2 3 4 5 86 3 4 5 86 3 4 5 86 3 4 5 86 2 3 4 56 4 2 3 4 56 4 2 3 4 56 4 2 3 4 56	1 2 3 4 5 M 2 3 4 5 M 2 3 4 0 4 2 3 4 M 2 3 4 5 M 2 3 4 5 M 2 3 4 5 M 2 3 4 5 M 2 3 4 0 4 2 4 0 4 2 3 4 0 4 2 3 4 0 4 2 3 4 0 4 2 3 4 0 4 2 3 4 0 4 2 3 4 0
	numu-purymer Lengtinomoporymer Length Number of Kepeat Units Number of Repeat Units Microhomology Length	numoporymer Lengumomoporymer Length Number of Repeat Units Number of Repeat Units Microhomology Length
	Ibp Deletion Ibp Insertion Collection Length) Constraint Length) Constraint Length) Constraint Length) Constraint Length) 640 C TO 2 3 4 5+ 2	1bp Deletion 1bp Insertion (Deletion Length) (D
		5 42%
	9 1224 9 1224 9 1224	8 20%
		ž 100
	1 2 3 4 5 56 2 3 4 56 4 2 3 4 56 2 3 4 55 2 3 4 5 56 3 4 5 56 3 4 5 56 2 3 4 56 4 56 4 2 3 4 56 4 56 4 56 4 56 4 56 4 56 4 56 4	1 2 3 4 5 8 4 3 5 4 4 2 3 4 5 4 3 4 5 8 4 3 4 5 8 4 3 4 5 5 4 3 4 5 8 4 3 4 5 6 4 2 3 4 6 4 2 3 4 6 4 2 3 4 6 4 2 3 4 5 4 1 2 3 1 2 3 1 2 3 4 5 + 2 1 2 3 4 5 + 2 1 2 3 4 5 + 2 1 2 3 4 5 + 2 1 2 3 4 5 + 2 1 2 3 4 5 + 2 1 2 3 4 5 + 2 1 2 3 4 5 + 2 1 2 3 4 5 + 2 1 2 3 4 5 + 2 1 2 3 4 5 + 2 1 2 3 4 5 + 2 1 2 3 4 5 + 2 1 2 3 4 5 + 2 1 2 3 4 5 + 2 1 4 5 + 2 1 4 5 + 2 1 4 5 + 2 3 + 2 3 +

late

early

early late

early



late

early late

early

late

early late

early

late

early late

Subsite



Tobacco

Tobacco

Subsite





а 18



b



ClusterD2 Cluster P

HNC clusters

Cluster

Cluster D1

ClusterD Cluster Cluster HNC clusters

Cluster

S

C റി 6 Cluster Cluster Cluster Cluster

HNC clusters



